Similar articles

• [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].

  Bergmann L. Bergmann L. Strahlenther Onkol. 2001 May;177(5):273-4. Strahlenther Onkol. 2001. PMID: 11398617 Clinical Trial. German. No abstract available.
• Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.

  Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M. Milla-Santos A, et al. Am J Clin Oncol. 2003 Jun;26(3):317-22. doi: 10.1097/01.COC.0000047126.10522.F9. Am J Clin Oncol. 2003. PMID: 12796608 Clinical Trial.
• Focus on anastrozole and breast cancer.

  Mokbel K. Mokbel K. Curr Med Res Opin. 2003;19(8):683-8. doi: 10.1185/030079903125002397. Curr Med Res Opin. 2003. PMID: 14687437 Review.
• Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

  Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Smith IE, et al. J Clin Oncol. 2005 Aug 1;23(22):5108-16. doi: 10.1200/JCO.2005.04.005. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998903 Clinical Trial.
• Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.

  Buzdar AU. Buzdar AU. Expert Rev Anticancer Ther. 2002 Dec;2(6):623-9. doi: 10.1586/14737140.2.6.623. Expert Rev Anticancer Ther. 2002. PMID: 12503208 Review.